Galapagos NV (NASDAQ:GLPG) Receives $25.33 Average Price Target from Analysts

Galapagos NV (NASDAQ:GLPG - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight research firms that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $25.33.

GLPG has been the topic of several research reports. Barclays reissued an "underweight" rating on shares of Galapagos in a research note on Thursday, January 23rd. TD Cowen cut Galapagos from a "strong-buy" rating to a "strong sell" rating in a research note on Thursday, January 9th. Finally, Morgan Stanley downgraded shares of Galapagos from an "equal weight" rating to an "underweight" rating and cut their price objective for the company from $31.00 to $22.00 in a research report on Friday, February 14th.

Galapagos Stock Up 0.4 %

Shares of NASDAQ:GLPG traded up $0.11 during trading on Friday, hitting $24.88. The stock had a trading volume of 70,693 shares, compared to its average volume of 255,478. The firm's fifty day moving average is $25.11 and its 200 day moving average is $26.84. Galapagos has a 12 month low of $22.36 and a 12 month high of $32.17.

Hedge Funds Weigh In On Galapagos

A number of institutional investors have recently bought and sold shares of the stock. R Squared Ltd purchased a new position in shares of Galapagos during the 4th quarter valued at $26,000. GAMMA Investing LLC grew its stake in shares of Galapagos by 77.4% during the fourth quarter. GAMMA Investing LLC now owns 2,233 shares of the biotechnology company's stock valued at $61,000 after buying an additional 974 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Galapagos by 5.9% in the fourth quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company's stock worth $711,000 after buying an additional 1,431 shares during the period. QRG Capital Management Inc. lifted its stake in shares of Galapagos by 21.7% during the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company's stock worth $288,000 after acquiring an additional 1,866 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Galapagos by 45.9% during the 4th quarter. BNP Paribas Financial Markets now owns 8,972 shares of the biotechnology company's stock valued at $247,000 after acquiring an additional 2,824 shares during the period. 32.46% of the stock is owned by institutional investors.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.